Last Updated on April 24, 2024 by The Health Master
Bengaluru: An expert panel of India’s drug regulator on Friday sought additional data from drug maker Dr. Reddy’s Laboratories on its Sputnik V C-19 vaccine trial, in its second such request after an initial evaluation in February.
The committee asked the company to submit a comparative analysis of late-stage immunogenicity data from both its Indian studies and an ongoing Russian study, as well as data on serious adverse events and positive cases reported till date.
Dr. Reddy’s has been conducting small clinical trials with Sputnik V in India under a deal with Russia’s wealth fund. Several Indian companies have signed deals to produce and supply over half a billion doses of the vaccine.
Also read:
List of Laboratory Instruments for Pharma & Cosmetics Industry
Remdesivir’s price must not cross Rs 1400: Maha Govt
J&J in discussions with Indian Govt single dose vaccine trial
Remdesivir: 2 held for black marketing, 284 vials seized
E-Pharmacies & OTC Drugs: High time for regulation
IPC invites bids for supply of Ref Std, Impurities from Pharma…
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
